Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Nov 1;57(21):3129-3133.
doi: 10.2169/internalmedicine.0806-18. Epub 2018 Jun 6.

Serial Manifestation of Acute Kidney Injury and Nephrotic Syndrome in a Patient with TAFRO Syndrome

Affiliations
Case Reports

Serial Manifestation of Acute Kidney Injury and Nephrotic Syndrome in a Patient with TAFRO Syndrome

Seigo Ito et al. Intern Med. .

Abstract

A 76-year-old woman suddenly developed anasarca and a fever, and an examination revealed thrombocytopenia, reticulin fibrosis, and acute kidney injury, yielding the diagnosis of thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly (TAFRO) syndrome. Renal replacement therapy and steroid treatment were soon started. Her proteinuria was minor at first; however, once the kidney function improved, nephrotic syndrome occurred. A kidney biopsy showed membranoproliferative glomerulonephritis-like glomerulopathy with massive macrophage infiltration. Although kidney dysfunction is often observed in TAFRO syndrome patients, its detailed mechanism is unclear. This case suggests that TAFRO syndrome involves both acute kidney injury with minor proteinuria and nephrotic syndrome, and these disorders can develop serially in the same patient.

Keywords: TAFRO syndrome; acute kidney injury; membranoproliferative glomerulonephritis-like glomerulopathy; nephrotic syndrome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Hyperplastic bone marrow in a patient with TAFRO syndrome (A, Hematoxylin and Eosin staining) accompanied by reticulin fibrosis (B, silver stain). (C) Immunoperoxidase staining for CD42b shows an increased number of megakaryocytes (original magnification, A, B, C, 100×). (D) The patient’s clinical course shows that steroid treatment resulted in an improved kidney function, increased platelet count (Plt), and decreased body weight (BW), waist size, and levels of inflammatory markers including C-reactive protein (CRP), interleukin (IL) -6, and vascular endothelial growth factor (VEGF). In contrast, urine protein (U-pro) increased after steroid therapy was started. Day X is the admission day. CHDF: Continuous hemodiafiltration, HD: hemodialysis, KBx: kidney biopsy, S-Cr: serum creatinine
Figure 2.
Figure 2.
Histological features of a kidney biopsy in a patient with TAFRO syndrome. (A) Lobulation of a glomerulus and mesangial proliferation can be seen in light microscopy sections (periodic acid-Schiff stain). (B) The glomerular capillary walls show focal double contouring (periodic acid-methenamine-silver stain). (C) Immunoperoxidase staining for CD68 (Nichirei Biosciences, Tokyo, Japan) shows many intraglomerular macrophages. (D) Double immunofluorescence staining for neutrophils (neutrophil elastase; Calbiochem, San Diego, USA) labeled with Alexa Fluor 488 (Thermo Fisher Scientific, Waltham, USA; green) and macrophages (CD68; Agilent, Santa Clara, USA) labeled with Alexa Fluor 594 (Thermo Fisher Scientific; red) shows massive macrophage infiltration within the tubulointerstitial area. The neutrophil infiltration is unremarkable. (E) Immunoperoxidase staining for CD34 (Agilent) shows prominently decreased CD34 immunoreactivity in some glomerular endothelial cells (arrows). Effacement of the podocyte foot processes (arrowheads) and mesangial interposition (Mes, F), expansion of the subendothelial space (asterisk, G), and infiltration of macrophages (MP, H) are shown in electron microscopy sections. There were no electron-dense deposits present (original magnification, A, B, C, 100×, D, 66×, E, 25×).

References

    1. Kawabata H, Takai K, Kojima M, et al. . Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53: 57-61, 2013. - PubMed
    1. Masaki Y, Kawabata H, Takai K, et al. . Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103: 686-692, 2016. - PubMed
    1. Iwaki N, Fajgenbaum DC, Nabel CS, et al. . Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91: 220-226, 2016. - PubMed
    1. José FF, Kerbauy LN, Perini GF, et al. . A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America. Medicine (Baltimore) 96: e6271, 2017. - PMC - PubMed
    1. Kawashima M, Usui T, Okada H, et al. . TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol 27: 1093-1097, 2017. - PubMed

Publication types